{
    "title": "110_hr4200",
    "content": "Amends the Internal Revenue Code to allow a general business tax credit for 50 of expenses paid for research and development of any qualified infectious disease product. Defines qualified infectious disease product as any antibiotic drug, antiviral, diagnostic test, biological product, or vaccine developed to treat, detect, prevent, or identify certain pathogens. Terminates such credit after 2012."
}